Materialise invests in Replasia for 3D-printed hip preservation implants

Materialise has invested in Replasia, a Belgian medtech startup developing patient-specific 3D-printed implants and anatomical analysis software for hip preservation. Replasia’s flagship product, the 3D Shelf Implant, is a patient-specific device placed outside the joint capsule for treating hip dysplasia, offering a less invasive alternative that preserves future treatment options. The startup began a first-in-human clinical investigation in the Netherlands in August 2025 and markets HipStudio, a planning service providing surgeons with anatomy-specific measurements. The investment follows Materialise’s transfer of its eyewear business to its management team, sharpening its focus on healthcare, which now represents 50% of company revenues.

This move fits a recurring pattern in medical AM: established software-to-service players acquiring or investing in early-stage clinical implant companies to extend their portfolio along the patient-care pathway. Replasia’s 3D Shelf Implant sits alongside Materialise’s existing aMace acetabular implants for complex revision cases, bridging from preservation to revision within the hip segment. The deal underscores how value capture in medical AM increasingly depends on owning both the surgical planning software and the implant design, not just the print service. For Materialise, this is a targeted expansion within a high-value orthopedic niche where patient-specific geometry and regulatory clearance create meaningful barriers to entry.

From an industry perspective, this is a measured portfolio adjustment rather than a market-shaking event. Materialise is deepening its orthopedic footprint without overextending into new verticals or taking on significant manufacturing risk. The key execution challenge will be navigating the regulatory pathway for the 3D Shelf Implant through CE-MDR and eventual FDA clearance, and demonstrating that the clinical evidence supports adoption beyond the initial Dutch trial sites. For buyers, this signals that Materialise intends to remain a comprehensive surgical planning and implant partner, not just a software licensor.